Log In Get Started
Press Releases May 27, 2026 08:00 AM

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics to Present at June Investor Conferences Highlighting Progress in Gene Therapy Pipeline

By Sofia Navarro FDMT

4D Molecular Therapeutics announced participation in upcoming June investor conferences, where company management will present and hold one-on-one meetings. The biotech firm is advancing late-stage gene therapy candidates targeting serious conditions such as wet age-related macular degeneration and cystic fibrosis, with multiple programs in clinical development but not yet FDA approved.

4DMT to Participate in Upcoming Investor Conferences
FDMT

Key Points

  • 4DMT will present at the Jefferies and Goldman Sachs Global Healthcare Conferences in early June 2026.
  • The company's lead product candidate, 4D-150, targets retinal diseases and is in Phase 3 trials, aiming to reduce treatment burden.
  • Another key program, 4D-710, is focused on cystic fibrosis and has demonstrated successful gene delivery in lungs via aerosol.
  • The company remains in clinical/preclinical stages with no current marketed products, maintaining a focus on biotechnology and gene therapy sectors.

EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in June.

Jefferies Global Healthcare Conference

Presentation Date:Wednesday, June 3, 2026Presentation Time:3:10 p.m. ET


Goldman Sachs 47th Annual Global Healthcare Conference

Presentation Date:Tuesday, June 9, 2026Presentation Time:2:00 p.m. ET


Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
[email protected]

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
[email protected]


Risks

  • All product candidates are investigational and not yet approved by the FDA, posing regulatory approval risk impacting company valuation and biotech investments.
  • Clinical trial outcomes remain uncertain; failure or delays especially in Phase 3 for 4D-150 could negatively affect company prospects and relevant healthcare subsectors.
  • Market adoption and reimbursement risks exist even if approved, affecting commercial success in ophthalmology and rare disease treatment markets.

More from Press Releases

Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026 DLH Announces Filing of New Shelf Registration Statement Jun 4, 2026 FutureCorp Space Acquisition 1 Announces Pricing of $200,000,000 Initial Public Offering Jun 4, 2026